Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2013

01-12-2013 | Original Article

Lysophosphatidic Acid Stimulates Activation of Focal Adhesion Kinase and Paxillin and Promotes Cell Motility, via LPA1–3, in Human Pancreatic Cancer

Authors: Yan Liao, Ganggang Mu, Lingli Zhang, Wei Zhou, Jun Zhang, Honggang Yu

Published in: Digestive Diseases and Sciences | Issue 12/2013

Login to get access

Abstract

Background

Pancreatic cancer is highly metastatic and with poor prognosis. In previous studies, lysophosphatidic acid (LPA) was shown to be a critical component of ascites which promoted the invasion and metastasis of pancreatic cancer. Two focal adhesion proteins, focal adhesion kinase (FAK) and paxillin, were crucially involved in cell migration, cytoskeleton reorganization, and the dynamics of focal adhesion.

Objectives

This study examined the involvement of LPA1–3 in LPA-induced activation of FAK and paxillin, and in cell motility, in pancreatic cancer PANC-1 cells.

Methods

Reverse transcriptase polymerase chain reaction analysis was used to examine mRNA expression of LPA receptors in PANC-1. Cellular protein expression of FAK and paxillin was analyzed by western blotting. The subcellular location of FAK and paxillin was visualized by immunofluorescence. Cell migration was measured by use of a transwell migration chamber.

Results

Three LPA receptors (LPA1, LPA2, and LPA3) were significantly expressed in PANC-1 cells. Treatment with LPA induced both time and dose-dependent tyrosine phosphorylation of FAK and paxillin. LPA also affected translocation of FAK and paxillin from cytoplasm to focal adhesions at the cell periphery and enhanced cell motility of PANC-1. Pretreatment with 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl)benzylsulfanyl)propanoic acid (Ki16425), an antagonist of LPA1 and LPA3, before LPA attenuated the LPA-induced tyrosine phosphorylation and redistribution of FAK and paxillin and abrogated LPA-induced cellular migration activity.

Conclusions

These results suggest LPA induces activation of FAK and paxillin via LPA1–3, which may contribute to the increased cell motility in human pancreatic cancer PANC-1 cells. Thus, an understanding of the regulation by LPA of cell motility in pancreatic cancer could identify novel targets for therapy.
Literature
1.
Ryder NM, Guha S, Hines OJ, et al. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. J Cell Physiol. 2001;186:53–64.PubMedCrossRef
2.
Komachi M, Tomura H, Malchinkhuu E, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 2009;30:457–465.PubMedCrossRef
3.
Kim MH, Park JS, Chang HJ, et al. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. J Cell Biochem. 2008;104:1102–1112.PubMedCrossRef
4.
Ramachandran S, Shida D, Nagahashi M, et al. Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. FEBS Lett. 2010;584:4077–4082.PubMedCrossRef
5.
Shida D, Fang X, Kordula T, et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008;68:6569–6577.PubMedCrossRef
6.
Zhang R, Wang J, Ma S, et al. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells. BMC Cell Biol. 2011;12:11.PubMedCrossRef
7.
Zhang H, Bialkowska A, Rusovici R, et al. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J Biol Chem. 2007;282:15541–15549.PubMedCrossRef
8.
Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279:6595–6605.PubMedCrossRef
9.
Komachi M, Sato K, Tobo M, et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci. 2012;103:1099–1104.PubMedCrossRef
10.
Leve F, Marcondes TG, Bastos LG, et al. Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells. Eur J Pharmacol. 2011;671:7–17.PubMedCrossRef
11.
Iwanicki MP, Vomastek T, Tilghman RW, et al. FAK, PDZ-RhoGEF and ROCKII cooperate to regulate adhesion movement and trailing-edge retraction in fibroblasts. J Cell Sci. 2008;121:895–905.PubMedCrossRef
12.
Jiang X, Jacamo R, Zhukova E, et al. RNA interference reveals a differential role of FAK and Pyk2 in cell migration, leading edge formation and increase in focal adhesions induced by LPA in intestinal epithelial cells. J Cell Physiol. 2006;207:816–828.PubMedCrossRef
13.
Nakamura K, Yano H, Uchida H, et al. Tyrosine phosphorylation of paxillin alpha is involved in temporospatial regulation of paxillin-containing focal adhesion formation and F-actin organization in motile cells. J Biol Chem. 2000;275:27155–27164.PubMed
14.
Sawada K, Morishige K, Tahara M, et al. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol. 2002;87:252–259.PubMedCrossRef
15.
Hashimoto K, Morishige K, Sawada K, et al. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro. Cancer. 2005;103:1529–1536.PubMedCrossRef
16.
Arita Y, Ito T, Oono T, et al. Lysophosphatidic acid induced nuclear translocation of nuclear factor-kappaB in Panc-1 cells by mobilizing cytosolic free calcium. World J Gastroenterol. 2008;14:4473–4479.PubMedCrossRef
17.
Stähle M, Veit C, Bachfischer U, et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci. 2003;116:3835–3846.PubMedCrossRef
18.
Lange K, Kammerer M, Saupe F, et al. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res. 2008;68:6942–6952.PubMedCrossRef
19.
Salazar EP, Rozengurt E. Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397. J Biol Chem. 2001;276:17788–17795.PubMedCrossRef
20.
Iwasaki T, Nakata A, Mukai M, et al. Involvement of phosphorylation of Tyr-31 and Tyr-118 of paxillin in MM1 cancer cell migration. Int J Cancer. 2002;97:330–335.PubMedCrossRef
21.
Hetey SE, Lalonde DP, Turner CE. Tyrosine-phosphorylated Hic-5 inhibits epidermal growth factor-induced lamellipodia formation. Exp Cell Res. 2005;311:147–156.PubMedCrossRef
22.
Moolenaar WH. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem. 1995;270:12949–12952.PubMedCrossRef
23.
Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J. 1998;12:1589–1598.PubMed
24.
Sun H, Ren J, Zhu Q, et al. Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. World J Gastroenterol. 2009;15:4547–4555.PubMedCrossRef
25.
Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 2003;63:1706–1711.PubMed
26.
Gibbs TC, Rubio MV, Zhang Z, et al. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells. Prostate. 2009;69:1493–1506.PubMedCrossRef
27.
Shin KJ, Kim YL, Lee S, et al. Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells. J Cancer Res Clin Oncol. 2009;135:45–52.PubMedCrossRef
28.
Shida D, Kitayama J, Yamaguchi H, et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res. 2004;301:168–178.PubMedCrossRef
29.
Ward JD, Dhanasekaran DN. LPA stimulates the phosphorylation of p130Cas via Gαi2 in ovarian cancer cells. Genes Cancer. 2012;3:578–591.PubMedCrossRef
30.
Jeong KJ, Park SY, Cho KH, et al. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene. 2012;31:4279–4289.PubMedCrossRef
31.
Li TT, Alemayehu M, Aziziyeh AI, et al. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res. 2009;7:1064–1077.PubMedCrossRef
32.
Tanabe E, Kitayoshi M, Yoshikawa K, et al. Loss of lysophosphatidic acid receptor-3 suppresses cell migration activity of human sarcoma cells. J Recept Signal Transduct Res. 2012;32:328–334.PubMedCrossRef
33.
Jung ID, Lee J, Lee KB, et al. Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells. Eur J Biochem. 2004;271:1557–1565.PubMedCrossRef
34.
Rusovici R, Ghaleb A, Shim H, et al. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta. 2007;1770:1194–1203.PubMedCrossRef
35.
Samadi N, Gaetano C, Goping IS, et al. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene. 2009;28:1028–1039.PubMedCrossRef
36.
Kam Y, Guess C, Estrada L, et al. A novel circular invasion assay mimics in vivo invasive behavior of cancer cell lines and distinguishes single-cell motility in vitro. BMC Cancer. 2008;8:198.PubMedCrossRef
37.
Gardner JA, Ha JH, Jayaraman M, et al. The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells. Pancreas. 2013;42:819–828.PubMedCrossRef
38.
Kato K, Yoshikawa K, Tanabe E, et al. Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells. Tumour Biol. 2012;33:1739–1744.PubMedCrossRef
39.
Yoshikawa K, Tanabe E, Shibata A, et al. Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells. Exp Cell Res. 2013;319:105–112.PubMedCrossRef
40.
Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004;279:17634–17639.PubMedCrossRef
41.
Hayashi M, Okabe K, Kato K, et al. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett. 2012;316:91–96.PubMedCrossRef
42.
Yamashita H, Kitayama J, Shida D, et al. Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol. 2006;93:30–35.PubMedCrossRef
43.
Luttrell LM, Daaka Y, Della Rocca GJ, et al. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem. 1997;272:31648–31656.PubMedCrossRef
44.
Linseman DA, Hofmann F, Fisher SK. A role for the small molecular weight GTPases, Rho and Cdc42, in muscarinic receptor signaling to focal adhesion kinase. J Neurochem. 2000;74:2010–2020.PubMedCrossRef
45.
Lee J, Jung ID, Chang WK, et al. p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase. Exp Cell Res. 2005;307:315–328.PubMedCrossRef
46.
Seufferlein T, Rozengurt E. Lysophosphatidic acid stimulates tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130. Signaling pathways and cross-talk with platelet-derived growth factor. J Biol Chem. 1994;269:9345–9351.PubMed
47.
Salazar EP, Hunger-Glaser I, Rozengurt E. Dissociation of focal adhesion kinase and paxillin tyrosine phosphorylation induced by bombesin and lysophosphatidic acid from epidermal growth factor receptor transactivation in Swiss 3T3 cells. J Cell Physiol. 2003;194:314–324.PubMedCrossRef
48.
Leopoldt D, Yee HF Jr, Saab S, et al. Tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin does not require extracellular signal-regulated kinase activation in Swiss 3T3 cells stimulated by bombesin or platelet-derived growth factor. J Cell Physiol. 2000;183:208–220.PubMedCrossRef
49.
Chrzanowska-Wodnicka M, Burridge K. Tyrosine phosphorylation is involved in reorganization of the actin cytoskeleton in response to serum or LPA stimulation. J Cell Sci. 1994;107:3643–3654.PubMed
50.
Barry ST, Critchley DR. The RhoA-dependent assembly of focal adhesions in Swiss 3T3 cells is associated with increased tyrosine phosphorylation and the recruitment of both pp 125FAK and protein kinase C-delta to focal adhesions. J Cell Sci. 1994;107:2033–2045.PubMed
51.
Sawada K, Morishige K, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res. 2002;62:6015–6020.PubMed
Metadata
Title
Lysophosphatidic Acid Stimulates Activation of Focal Adhesion Kinase and Paxillin and Promotes Cell Motility, via LPA1–3, in Human Pancreatic Cancer
Authors
Yan Liao
Ganggang Mu
Lingli Zhang
Wei Zhou
Jun Zhang
Honggang Yu
Publication date
01-12-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2878-4

Other articles of this Issue 12/2013

Digestive Diseases and Sciences 12/2013 Go to the issue

Original Article

Epidemiology of Clostridium difficile-Associated Disease (CDAD): A Shift from Hospital-Acquired Infection to Long-Term Care Facility-Based Infection

Original Article

Effects of Peroxisome Proliferator-Activated Receptor-γ Activation on Apoptosis in Rats with Acute Pancreatitis

Original Article

Clostridium Butyricum MIYAIRI 588 Improves High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats

Original Article

Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

Original Article

African–Americans, Hispanic Americans, and Non-Hispanic Whites Without GERD or Reflux Symptoms Have Equivalent 24-h pH Esophageal Acid Exposure

Stanford Multidisciplinary Seminars

Infliximab for the Treatment of Granulomatous Peritonitis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits